We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class...
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with...
WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.12 | -2.88461538462 | 4.16 | 4.18 | 3.42 | 54867 | 3.65774126 | CS |
| 4 | -0.76 | -15.8333333333 | 4.8 | 5.83 | 3.42 | 43127 | 4.54308251 | CS |
| 12 | 0.79 | 24.3076923077 | 3.25 | 5.83 | 2.62 | 70440 | 4.0659681 | CS |
| 26 | 1.94 | 92.380952381 | 2.1 | 5.83 | 1.66 | 140516 | 3.25384776 | CS |
| 52 | -2.26 | -35.873015873 | 6.3 | 6.89 | 1.66 | 125312 | 3.72274379 | CS |
| 156 | -32.32 | -88.8888888889 | 36.36 | 45.33 | 1.66 | 189939 | 13.6766097 | CS |
| 260 | -21.72 | -84.3167701863 | 25.76 | 95.375 | 1.66 | 193033 | 20.82827286 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
